[Nirsevimab (prevention of RSV disease) – Benefit assessment according to §35a Social Code Book V]

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018013127
German
Original Title: Nirsevimab (Sekundärprophylaxe von RSV-Erkrankungen der unteren Atemwege)
Details
Project Status: Completed
URL for project: https://www.iqwig.de/projekte/a24-27.html
Year Published: 2024
URL for published report: https://www.iqwig.de/download/a24-27_nirsevimab_nutzenbewertung-35a-sgb-v_v1-1.pdf
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
DOI: https://doi.org/10.60584/A24-27_V1.1
MeSH Terms
  • Respiratory Syncytial Virus Infections
  • Respiratory Syncytial Viruses
  • Infant, Newborn
  • Antibodies, Monoclonal, Humanized
  • Antiviral Agents
  • Infant
Keywords
  • Nirsevimab
  • Respiratory Syncytial Virus Infections
  • Infant – Newborn
  • Infant
  • Benefit Assessment
Contact
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.